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Treatment effectiveness studies examine changes in outcomes. Inconsistencies in reported outcomes and the tools used to measure these, with missing outcome data and outcome reporting bias are often seen across studies (1). Consistency in outcomes is essential to allow direct comparison of effects. Inconsistency hinders evidence syntheses, limiting their usefulness with downstream negative impact on care quality. The use of core outcomes is required to improve the translation of evidence into practice (2). 

We wanted to examine if quality of outcome reporting was linked to other publication features. Bladder pain syndrome (BPS) (formerly known as interstitial cystitis and painful bladder syndrome), a common condition associated with considerable disability  ADDIN EN.CITE (3, 4), has trials and reviews evaluating various treatments to achieve symptomatic control. These outcomes are measured using a range of scales and scores. Any chronic condition would serve as a good exemplar to empirically address our questions but we chose BPS as this condition is of particular interest to the authors who are assessing the evidence on efficacy of treatments in BPS.  We acknowledge the lack of understanding around the aetiology of this condition and consensus on diagnosing and managing it, despite recent guidelines from the American Urological Association (5).





Our systematic review was conducted prospectively deploying a protocol based on contemporary methods and reported in accordance with the PRISMA statement (6).

Search strategy
Literature searches were conducted in the following databases covering time period from database inception until August 2013: the Cochrane Library, EMBASE (1980-2013), Medline (1950-2013), CINAHL (1981-2013) and LILACS (1982-2013). Grey literature was searched through SIGLE (1990-2013). There were no language restrictions. We used MeSH headings, their keywords and variants for ‘interstitial cystitis’ or ‘painful bladder syndrome’ or ‘bladder pain syndrome’ combined using the Boolean operator ‘and’ with the term ‘systematic review’ or its word variants in the title or abstract. A hand search of bibliographies from relevant articles and conference proceedings of the International Continence Society was performed to identify articles not electronically cited.  

Study selection and data extraction
All systematic reviews, defined as those that searched in at least two databases and used PRISMA or predecessor guidelines for reporting, evaluating treatments for BPS were included. Primary and secondary outcomes were recorded along with the measurement tools or questionnaires used to capture the outcome. This was usually in the form of patient-rated improvement scales (5). The type of journal (general or specialist) studies were published in was recorded, along with sources of pharmaceutical funding and any sample size calculations performed for randomised controlled trials (RCTs). The impact factor in the year of publication for both systematic reviews and RCTs was noted. All data were extracted in duplicate by two independent researchers (SAT, RNR) using an electronic data extraction form. The results were discussed and disagreements resolved through consensus. 

Quality assessments 
Quality assessment for outcomes reported within each systematic review and RCT was assessed using the following six questions (7): if a primary outcome was stated (1-point), if a clear definition was provided for reproducible measurement (1-point), if a secondary outcome was stated (1-point), if a clear definition was provided for reproducible measurement (1-point), if the authors explained the use of the outcomes (1-point) and if methods were used to enhance quality of measures, for example repeating measures or training in use of measurement tools (1-point). There is no rating system for the scores, so an arbitrary level of  4 was used by the authors to represent ‘good’ quality. The development of core outcome sets is a relatively new concept. Much work has been done to develop specific questions to assess the chosen outcome measures and so the six questions above were chosen, as used in published literature on core outcome development (7).

Study quality assessment was undertaken for all systematic reviews using an 11-point AMSTAR (assessment of multiple systematic reviews) measurement tool. This is a standardised checklist assessing the methodology of the systematic review, along with study characteristics, quality assessment, publication bias assessment and conflict of interest declaration, where all 11 questions can be answered as yes, no, cannot be answered or not applicable. ‘High’ quality is assigned to scores eight to 11, ‘medium’ quality to scores four to seven and ‘low’ quality to 0 to three (8). The Jadad criteria were used to assess quality in RCTS. This is a commonly used scoring system, which evaluates randomisation and blinding along with the methodology used and accounts for patient who drop out of the study, where all five questions are answered as yes or no. Scores ranged from 0-5, with ‘good’ quality assigned to scores  3 (9). Both study quality assessment scores were transformed into a scale from 0-100 for graphical representation and correlation analysis. 

Data synthesis
Descriptive characterisations of studies were tabulated. Graphical representations were prepared. Spearman’s rank correlation with 95% confidence intervals (CI) was calculated for quality of reporting outcomes versus overall study quality assessment and journal impact factor in the year of publication. Multiple regression analysis was undertaken using StatsDirect version 2.7.9 to assess the relationship of quality of outcomes reported with study quality adjusting for impact factor, year of publication, commercial funding and study and journal type.  

Results
Figure 1 summarises the selection of articles, which were all in English. Eight systematic reviews were included with a total of 1732 patients  ADDIN EN.CITE (10-17). Four articles were excluded; three did not adhere to the definition of a systematic review and one did not affect patients with BPS  ADDIN EN.CITE (18-21). There were various outcomes and measurement tools within each study (Table 1). There were 28 unique RCTs  ADDIN EN.CITE (22-47). Five outcomes were identified; urinary symptoms, pain, quality of life, general wellbeing and bladder capacity. Seven outcome tools were used to measure urinary symptoms in 28 RCTs (100%), five to measure pain in 18 RCTs (64%), six for quality of life in 11 RCTs (39%), one for general wellbeing in 10 RCTS (36%) and one for bladder capacity in 12 RCTs (43%). In quality of life measurement tools we used the general or ‘physical’ component, rather than the emotional or ‘mental’ component referred to in the SF 36 questionnaire. The AMSTAR tool for quality of systematic reviews scored a mean of 5.63 (95% CI 3.26 – 7.99). The Jadad criteria for quality in RCTS scored mean of 3.13 (95% CI 2.58 – 3.67). 

Half of the systematic reviews were published in specialists’ urology or urogynaecology journals (n= 4), 13% (n = 1) in a general obstetrics and gynaecology journal and 38% (n = 3) in non-women’s health journals. All of the RCTs were published in specialty urology or urogynaecology journals (n = 28). In 46% (n = 15) of RCTS a sample size calculation was performed. None of systematic reviews and 33% (n = 8) of RCTs had pharmaceutical company funding. 

The quality of outcomes reporting was assessed in 21 RCTs and seven systematic reviews (figure 2). Four original RCT papers could not be obtained despite all attempts to contact the authors, so were excluded from this analysis, as accurate quality assessment could not be performed from the limited information in the study abstract  ADDIN EN.CITE (28, 36, 48, 49). The mean score for quality of outcomes reported was 1.63 (95% CI 0.29 – 2.96) for systematic reviews and 3.25 (95% CI 2.80 – 3.70) for RCTs. The quality of outcome reporting in 13% (n = 1) of systematic reviews was deemed good quality and 33% (n = 8) of RCTS (figure 2). Primary outcome reporting was no different (4 versus 21, 50% versus 88%, p = 0.51), but secondary outcomes were more frequently reported in RCTs compared to systematic reviews (1 versus 11, 13% versus 46%, p = 0.003). 

Figures 3 show the relationship between quality of outcomes reporting with impact factor in the year of publication and study quality in included systematic reviews and RCTs. One systematic review and three RCTs were excluded, as information about the journal impact factor in the year of publication could not be obtained  ADDIN EN.CITE (15, 22, 35, 45). The quality of outcomes reported showed correlation with study quality (0.90, 95% CI 0.79 - 0.95, p = <0.0001) but not with journal impact factor (0.07, 95% CI -0.31 – 0.43, p = 0.35) using Spearman’s rank coefficient.  Multivariable linear regression analysis confirmed the positive relationship between outcome reporting quality and study quality (β= 0.05, p < 0.0001) with, adjusting for effects of study type, impact factor and journal type (table 2). Systematic reviews versus RCTs (β = -1.24, p < 0.0001), specialist versus general journals (β = -0.41, p = 0.03), and lower versus higher impact factor (β = -0.07, p = 0.02) were associated with outcome reporting quality.

Discussion
Various outcomes and measurement tools were used to assess treatment effectiveness in BPS. There is a general lack of RCTs for treatment effectiveness in BPS with the majority of studies being observational. There was poor quality of outcomes reporting. Reporting of secondary outcomes was better in individual RCTs compared to systematic reviews. The quality of included systematic reviews and RCTs was variable. The highest quality systematic review was by Dawson et al assessing intravesical treatments for BPS, which clearly stated outcome measures and performed well using the quality assessment tools but this may be explained by the fact it is a Cochrane collaboration publication which needs to adhere to the Cochrane guidance and hence incorporates all expected elements of reporting a systematic review (10). Conversely, the publication in the highest impact journal by Mangera et al had the lowest quality assessment score as it did not describe primary or secondary outcomes (12). There was a relationship between the quality of outcomes reported and the quality of a study but not with journal impact factor at publication. This relationship remained significant in a multivariable analysis. It is interesting to note the lack of correlation with journal impact factor which may suggest the authors with good quality studies do not aim to publish in high impact journals, resorting for speciality specific, often lower ranking journals.  

This review performed systematic assessment of all available literature with no language barriers. All five outcomes were assessed using a variety of patient-reported questionnaires, which comprised of composite symptom and sign scores, along with visual analogue scales. This heterogeneity would make comparison of effects on treatment very difficult with an inability to evaluate their impact on disease (50). Many patient-reported questionnaires lack the ability to be truthful, are unfeasible to replicate and do not have discriminative power to gauge the reliability and sensitivity of the measurement tool (51). The relationship we observed between quality of outcomes reporting and overall study quality merits consideration. The RCTs were international with different patient populations so no meaningful comparisons could be made relating to ethnicity. 

This review has identified five different outcomes to assess treatments for BPS which can serve as a starting point for the development of a core outcome set involving a Delphi panel survey of stakeholders, including patient representatives, through consensus and would enable prioritisation of outcomes (52). Outcome measures can be prioritised using the Grading, Recommendations, Assessment, Development and Evaluation (GRADE) working group recommendation scale. This enables improved standardisation and transparency of results by prioritising outcomes from ‘critically important’ to ‘not important’  ADDIN EN.CITE (53, 54). 

There is an attempt to standardise terminology in urogynecology  ADDIN EN.CITE (55, 56). Standardised, validated tools with clear reporting on time of testing will be needed to allow repeatable results when developing an inventory of core outcomes (7). There is a need for a set of core outcomes for common gynaecological conditions in addition to explicitness of intended primary and secondary outcomes in order to improve the transparency of results in trials, reviews and guidelines. Symptom severity and general physical and mental quality of life are important outcome measures. There are several validated disease-specific questionnaires used for BPS but no single internationally adopted one.  Delphi panels of specialists may be used to develop a single symptom-based questionnaire, which incorporates the five core outcomes identified in this paper.
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Table 1: Characteristics of systematic reviews for treatments of bladder pain syndrome.

Systematic review		Impact factor (AMSTAR)	Treatment		No. of RCTs  	Total no. of studies		Outcome		Measurement tool		Number of RCTs	
 (Author, year)								(no. of patients)	(total no. of patients)						per outcome	
Srivastava, 2012		Not documented (3)	Sacral neuromodulation	1 (22)		11 (480)			Pain			VAS			1
														Quality of life		GRA, SF 36, BDI		0
														Urinary symptoms		ICPI, PUF		0
														Bladder capacity		Not documented		0
Dawson, 2009		4.65	(11)		Intravesical treatments	8 (586)		9 (616)			Pain			VAS, NRS		3
														Quality of life		ICSI, Rand 36		5
Urinary symptoms		ICSI, GRA, PUF		4
														Bladder capacity		Voiding diary, urodynamics	4
														Economic outcomes	Not documented		0
Dimitrakov, 2007		8.39	(6)		Pharmacological		21 (1470)		21 (1470)			Urinary symptoms		ICSI/PI, voiding diary	21 
Global status		Not documented		0




Global quality of life	CPSI, PSS, GICS, AUA SI	1
Matsuoka, 2012		2.17	(5)		Intravesical treatments	5 (596)		5 (596)			Pain			VAS, PUF		3
														Quality of life		SF 36, Rand 36		0
Urinary symptoms		GRA, ICSI		5
														Bladder capacity		Urodynamics		3
Mourtzoukou, 2008		2.38	(2)		Intravesical resiniferatoxin	3 (203)		6 (225)			Pain			VAS, PUF		3
														Quality of life		Not documented		0
														Urinary symptoms		GRA, ICSI, voiding diary	3
Tirlapur, 2013		1.85	(7)		Neuromodulation		1 (56)		1 (56)			Pain			ICSI/PI			1
														Quality of life		ICSI/PI			1
														Urinary symptoms		SF 36			1
Tirumuru, 2012		1.73	(7)		Intravesical Botulinum 	3 (155)		10 (260)			Pain			VAS			2
toxin A								Urinary symptoms		BFLUTS, GRA, IIQ, ICSI, 	2
											KHQ	
														Bladder capacity		Urodynamics		2
														Quality of life		IPPS, UDI		2






Figure 2: Quality of outcomes reported for systematic reviews and randomised controlled trials (RCTs) 

                            	
                   











Impact factor at publication			-0.08	0.02			-0.07	0.02






+ measurement details in methodology section
* Based on best sub-set regression









